Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
EyePoint stock crashed Monday after its eye disease treatment, Duravyu, missed the mark in a final-phase study. The post The Surprising Reason EyePoint Just Crashed 69% appeared first on Investor’s Business Daily.
Eton stock catapulted to a record high Friday after the biotech company smashed second-quarter sales forecasts and hiked its guidance. The post Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High appeared first on Investor’s Business Daily.
Omeros stock rocketed to a five-year high Thursday on blowout second-quarter results for its new treatment for transplant complications. The post This Biotech Stock Just Gapped Up To A Five-Year High; Here’s Why appeared first on Investor’s Business Daily.
On the IBD 50 and the latest list of new buys by top funds, Ligand stock targets a breakout but faces this test first. The post Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock appeared first on Investor’s…
Liquidia topped Wall Street’s second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits. The post Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry appeared first on Investor’s Business Daily.
Hims stock fell late Monday after second-quarter losses came in bigger than expected, upsetting a sales beat. The post Hims & Hers Topples As Deeper-Than-Expected Losses Outweigh Quarterly Beat appeared first on Investor’s Business Daily.
Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. The post Why Vertex Pharma Popped, As A Key Rival Plummeted 90% appeared first on Investor’s Business Daily.
The S&P 500 and Dow Jones hit highs while the Nasdaq raced above key levels as oil prices and yields fell. Palantir, Cloudflare and SpaceX were big movers amid earings. The post Stock Market Rally Powers Ahead; SpaceX, Palantir, Sandisk…
Halozyme stock rocketed to a record high Friday as its newer Enhanze-tied products start driving incremental growth. The post Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume appeared first on Investor’s Business Daily.
